Metabolomics Panel Associated with Cystic Fibrosis-Related Diabetes Toward Biomarker Discovery

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2024 Aug 5

PMID 39100315

Authors

Muhammad Mujammami

Refat M Nimer

Maha Al Mogren

Reem AlMalki

Mohamad S Alabdaljabar

Hicham Benabdelkamel

Anas M Abdel Rahman

Affiliations

Soon will be listed here.

Abstract

The most prevalent comorbidity among cystic fibrosis (CF) patients is cystic fibrosis-related diabetes (CFRD). CFRD has been linked to one of the worse clinical outcomes and a higher mortality. Improved clinical results have been related to earlier diagnosis and treatment of CFRD. Therefore, the present study aimed to investigate the metabolome of human serum of patients with CFRD. This might aid in identifying novel biomarkers linked with the pathophysiology of CFRD and its diagnosis. The liquid chromatography-high-resolution mass spectrometry (LC-HRMS) metabolomics approach was utilized for serum samples from patients with CF ( = 36) and healthy controls ( = 36). Nine patients in the CF group had CFRD, and 27 were non-CFRD patients (nCFRD). A total of 2328 metabolites were significantly altered in CF compared with the healthy control. Among those, 799 significantly dysregulated metabolites were identified between CFRD and nCFRD. Arachidonic acid (AA), ascorbate, and aldarate metabolism were the most common metabolic pathways dysregulated in CF. l-Homocysteic acid (l-HCA) levels were significantly reduced in CF and CFRD compared to the control and nCFRD, respectively. In addition, gamma-glutamylglycine and l-5-hydroxytryptophan (5-HTP) had the highest discrimination between CFRD and nCFRD with AUC (0.716 and 0.683, respectively). These biomarkers might serve as diagnostic biomarkers and aid in understanding potential metabolic changes linked to CF and CFRD.

References

Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z . Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989; 245(4922):1066-73. DOI: 10.1126/science.2475911. View

Moran A, Pillay K, Becker D, Acerini C . ISPAD Clinical Practice Consensus Guidelines 2014. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2014; 15 Suppl 20:65-76. DOI: 10.1111/pedi.12178. View

NTimbane T, Comte B, Mailhot G, Berthiaume Y, Poitout V, Prentki M . Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress. Clin Biochem Rev. 2009; 30(4):153-77. PMC: 2791770. View

Moran A, Brunzell C, Cohen R, Katz M, Marshall B, Onady G . Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010; 33(12):2697-708. PMC: 2992215. DOI: 10.2337/dc10-1768. View

Sankararaman S, Hendrix S, Schindler T . Update on the management of vitamins and minerals in cystic fibrosis. Nutr Clin Pract. 2022; 37(5):1074-1087. PMC: 9544449. DOI: 10.1002/ncp.10899. View

Lim H, Choi Y, Park W, Lee T, Ryu S, Kim S . Phosphatidic acid regulates systemic inflammatory responses by modulating the Akt-mammalian target of rapamycin-p70 S6 kinase 1 pathway. J Biol Chem. 2003; 278(46):45117-27. DOI: 10.1074/jbc.M303789200. View

Okunishi K, Peters-Golden M . Leukotrienes and airway inflammation. Biochim Biophys Acta. 2011; 1810(11):1096-102. PMC: 3136588. DOI: 10.1016/j.bbagen.2011.02.005. View

Wei L, Hongping H, Chufang L, Cuomu M, Jintao L, Kaiyin C . Effects of Shiwei Longdanhua formula on LPS induced airway mucus hypersecretion, cough hypersensitivity, oxidative stress and pulmonary inflammation. Biomed Pharmacother. 2023; 163:114793. DOI: 10.1016/j.biopha.2023.114793. View

DiBattista A, McIntosh N, Lamoureux M, Y Al-Dirbashi O, Chakraborty P, Britz-McKibbin P . Metabolic Signatures of Cystic Fibrosis Identified in Dried Blood Spots For Newborn Screening Without Carrier Identification. J Proteome Res. 2018; 18(3):841-854. DOI: 10.1021/acs.jproteome.8b00351. View

10.

Vangipurapu J, Stancakova A, Smith U, Kuusisto J, Laakso M . Nine Amino Acids Are Associated With Decreased Insulin Secretion and Elevated Glucose Levels in a 7.4-Year Follow-up Study of 5,181 Finnish Men. Diabetes. 2019; 68(6):1353-1358. DOI: 10.2337/db18-1076. View

11.

Comte B, Monnerie S, Brandolini-Bunlon M, Canlet C, Castelli F, Chu-Van E . Multiplatform metabolomics for an integrative exploration of metabolic syndrome in older men. EBioMedicine. 2021; 69:103440. PMC: 8237302. DOI: 10.1016/j.ebiom.2021.103440. View

12.

Jaber M, Benabdelkamel H, Dahabiyeh L, Masood A, AlMalki R, Musambil M . The metabolomics approach revealed a distinctive metabolomics pattern associated with hyperthyroidism treatment. Front Endocrinol (Lausanne). 2022; 13:1050201. PMC: 9685425. DOI: 10.3389/fendo.2022.1050201. View

13.

Wheelock C, Strandvik B . Abnormal n-6 fatty acid metabolism in cystic fibrosis contributes to pulmonary symptoms. Prostaglandins Leukot Essent Fatty Acids. 2020; 160:102156. DOI: 10.1016/j.plefa.2020.102156. View

14.

Endo Y . Evidence that the accumulation of 5-hydroxytryptamine in the liver but not in the brain may cause the hypoglycaemia induced by 5-hydroxytryptophan. Br J Pharmacol. 1985; 85(3):591-8. PMC: 1916514. DOI: 10.1111/j.1476-5381.1985.tb10553.x. View

15.

Nguyen A, Haas D, Bouchard M, Quon B . Metabolomic Biomarkers to Predict and Diagnose Cystic Fibrosis Pulmonary Exacerbations: A Systematic Review. Front Pediatr. 2022; 10:896439. PMC: 9192952. DOI: 10.3389/fped.2022.896439. View

16.

Granados A, Chan C, Ode K, Moheet A, Moran A, Holl R . Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis. J Cyst Fibros. 2019; 18 Suppl 2:S3-S9. DOI: 10.1016/j.jcf.2019.08.016. View

17.

Candi E, Tesauro M, Cardillo C, Lena A, Schinzari F, Rodia G . Metabolic profiling of visceral adipose tissue from obese subjects with or without metabolic syndrome. Biochem J. 2018; 475(5):1019-1035. DOI: 10.1042/BCJ20170604. View

18.

Siwamogsatham O, Alvarez J, Tangpricha V . Diagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis. Curr Opin Endocrinol Diabetes Obes. 2014; 21(5):422-9. PMC: 4326081. DOI: 10.1097/MED.0000000000000096. View

19.

Lin Y, Keenan K, Gong J, Panjwani N, Avolio J, Lin F . Cystic fibrosis-related diabetes onset can be predicted using biomarkers measured at birth. Genet Med. 2021; 23(5):927-933. PMC: 8105168. DOI: 10.1038/s41436-020-01073-x. View

20.

Kelly A, Moran A . Update on cystic fibrosis-related diabetes. J Cyst Fibros. 2013; 12(4):318-31. DOI: 10.1016/j.jcf.2013.02.008. View